AMEX RESUMED MAIA BIOTCHN ORD
29/07/2022 20:34
AMEX RESUMED MAIA BIOTCHN ORD MAIA.A
Recent news on Maia Biotechnology
See all newsBrief: Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr In 3l Nsclc
Brief: Maia Biotechnology - To Terminate At The Market Offering Agreement Effective May 23, 2026 - SEC Filing
Brief: Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
MAIA Biotechnology plunges after $30 million share sale